12:00 AM
 | 
May 05, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hydrocodone bitartrate ER: Clinical trial data

A double-blind, crossover trial in 35 healthy, non-dependent recreational opioid drug users showed that Purdue's abuse-deterrent, once-daily hydrocodone bitartrate ER when given either intact or chewed met the primary endpoint of lower drug liking scores measured up to 36 hours after dosing using a VAS vs. hydrocodone solution. Compared to hydrocodone solution, the proportion of patients with a >=30% reduction in maximum drug liking score was 83% for intact abuse-deterrent hydrocodone, 69% for chewed abuse-deterrent hydrocodone and 17% for a milled abuse-deterrent hydrocodone. Compared to hydrocodone solution, the proportion of patients with a >=50% reduction in maximum drug liking score was 74% for intact abuse-deterrent hydrocodone, 60% for chewed abuse-deterrent hydrocodone and 9% for milled abuse-deterrent hydrocodone.

A double-blind, crossover trial in 31 healthy, non-dependent recreational opioid drug users showed that Purdue's abuse-deterrent, once-daily hydrocodone bitartrate ER when given intranasally...

Read the full 681 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >